foxo4-dri senolytic peptide human trial The disordered p53 transactivation domain is the target of FOXO4 and the compound FOX04-DRI - Apollo Peptide Sciences
Pay in 4 interest-free payments of $6.71 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26

























